Webinar
Transforming manual data curation through Agentic AI and LLMs: How Biorelate's Galactic AI™ will power the future of Drug Discovery
July 10, 2025 03:30 PM Europe/London
60min webinar
Thursday July 10th 3.30pm-4.30pm BST, 4.30-5.30pm CEST, 10.30-11.30am EDT, 7.30-8.30am PDT
This webinar will address the key business and research successes with AI from teams across large pharma and smaller biotechs, with exciting new insights and impactful examples.
KEYNOTE TALK: Alex Gutteridge, Vice President of Digital Biology at Novo Nordisk, will deliver the keynote talk at the end of the webinar: ‘Can machines really (help us) understand the biology of target discovery?’
Can’t make the webinar time? Registering will grant you early access to the recording link.
Follow Biorelate on LinkedIn for more drug discovery webinars
Alex Gutteridge
Alex has worked in the pharma and biotech industry applying data and AI to drug discovery and development for 15 years with positions at Pfizer, GSK, Lonza and Enedra and Dunad Therapeutics. Now at Novo Nordisk, Alex leads a multi-disciplinary group of computational biologists, geneticists and epidemiologists aiming to put data and AI at the centre of Novo Nordisk’s quest to defeat serious chronic diseases like diabetes and obesity.
Richard Smith
Richard leads data and engineering at Healx, an AI enabled tech bio company discovering treatments to meet a huge unmet need in rare diseases. The data team at Healx integrate diverse scientific data sources to enable computational predictions and scientific rationale of drug candidates. Richard has worked for over 20 years in industry and academia building databases and tools to help answer scientific questions.
James Somauroo
James is the co-founder of SomX, a full-service communications and creative agency for healthtech, biotech & pharma companies. He is the editor-in-chief of Healthtech Pigeon and Biotech Dodo, writes for Forbes as a contributor about healthtech, startups and innovation, and also hosts The Healthtech Podcast. James holds degrees in medicine, biomedical sciences and education and is a guest lecturer on healthtech innovation and entrepreneurship at universities around the world.
Ben Sidders
Dr Ben Sidders, Chief Scientific Officer at Biorelate, has been working at the forefront of pharma data science for the last two decades. Formerly Executive Director and Head of Early Data Science within Oncology R&D at AstraZeneca, responsible for advancing the company’s understanding of disease through computational oncology, Ben also previously spent eight years at Pfizer, and has extensive experience of many aspects of drug discovery for major pharma. He is especially passionate about immuno-oncology, network biology and the role of bioinformatics within drug discovery. Ben has a PhD in Molecular Biology & Bioinformatics from the University of London where his thesis focused on the development of predictive markers for the diagnosis of asymptomatic Tuberculosis. He holds patents for two clinical diagnostics and has authored over 30 scientific publications.
Daniel Jamieson
Dr. Daniel Jamieson is the founder and CEO of Biorelate Ltd., a cutting-edge tech-bio at the forefront of using data science to revolutionise pharmaceutical research. Under his leadership, Biorelate has become a world leader in leveraging advanced data science methods to extract critical knowledge from vast amounts of pharmaceutical data and literature, significantly enhancing the discovery of novel biopharmaceuticals.
Tom Todd
Tom is a data science leader focused on managing, shaping and delivering machine learning projects.